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Abstract The stimulatory effects of gabapentin on the activities
of two types of glutamate dehydrogenase (GDH) isoproteins
homogeneously purified from bovine brain have been studied at
various conditions. When the effects of different gabapentin
concentrations on GDH activities were studied in the direction of
reductive amination of 2-oxoglutarate with NADPH as a
coenzyme, a marked activation was observed for both isopro-
teins, whereas both isoproteins showed activation to a lesser
extent with NADH as a coenzyme. Stimulatory effects of
gabapentin on GDH activities in the direction of the oxidative
deamination of glutamate were also observed, but to a much
lesser extent than reductive amination. There were big differ-
ences between the two GDH isoproteins in their sensitivity to the
action of gabapentin. The largest activation was observed with
GDH II when NADPH was used as a coenzyme. Half-maximal
stimulation was reached at around 1.5 mM. Gabapentin relieved
the inhibition of GDH isoproteins by GTP and this resulted in an
increase in the apparent activation by gabapentin in the presence
of GTP. 2-Oxoglutarate was found to give rise to high substrate
inhibition and gabapentin reduced the substrate inhibition in the
presence of 0.2 mM NADH. Since there are neurodegenerative
disorders in which GDH activity is decreased, the therapeutic
modulation of the activity of this enzyme may be clinically useful.
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1. Introduction
Glutamate is a major excitatory neurotransmitter [1] and is
also known to be the immediate precursor in the biosynthesis
of Q-aminobutyric acid (GABA), a widely distributed inhibi-
tory neurotransmitter. Due to its neurotoxic potential, gluta-
mate may be involved in the pathogenesis of human degener-
ative disorders [2]. One enzyme central to the metabolism of
glutamate is glutamate dehydrogenase (GDH) (EC 1.4.1.3).
GDHs are a family of enzymes which catalyze the reversible
deamination of L-glutamate to 2-oxoglutarate using NAD,
NADP or both as coenzymes [3]. Since the pathology of the
disorders associated with GDH defects is restricted to the
brain, the enzyme may be of particular importance in the
biology of the nervous system. The importance of the patho-
physiological nature of the GDH-de¢cient neurological disor-
ders has attracted considerable interest [4]. The enzyme iso-
lated from a patient with a variant form of multisystem
atrophy displayed a marked reduction of one of the GDH
isoproteins [5,6]. The origin of the GDH polymorphism is
not known. The presence of four di¡erently sized mRNAs
and multiple gene copies for GDH in the human brain has
been reported [6]. A novel cDNA encoded by an X chromo-
some-linked intronless gene has also been isolated from hu-
man retina [7].
It is only in recent years that the three-dimensional struc-
ture of GDH from microorganisms has become available
[8,9]. There is, however, relatively low identity between micro-
bial and mammalian GDHs. Very recently, crystallization of
bovine liver GDH was reported for the ¢rst time from mam-
malian sources [10]. However, remarkably little is known
about the detailed structure of mammalian GDH, especially
the brain enzymes. We have previously isolated two types of
GDH isoproteins (designated GDH I and GDH II) from bo-
vine brain [11] and the regulatory properties of the GDH
isoproteins have been reported [12^14]. Our work also led
to the ¢nding that GDH is present in bovine brain in ‘heat-
labile (GDH I)’ and ‘heat-stable (GDH II)’ forms [11]. Similar
results were reported by other investigators showing that re-
duction of GDH activity in patients with neurodegenerative
disorders was largely limited to the heat-labile form [15]. It
has been reported that the activities of the GDH isotypes
di¡er in their relative resistance to thermal inactivation, de-
tergent extractability, and allosteric regulation characteristics
[16,17]. To our knowledge, comparison of the detailed struc-
ture and functions of any GDH isoproteins has rarely been
reported. It is, therefore, essential to have a detailed structural
and functional description of the various types of brain GDH
to elucidate the pathophysiological nature of the GDH-de¢-
cient neurological disorders.
Gabapentin (1-(aminomethyl)cyclohexaneacetic acid) is a
novel anticonvulsant drug that is orally active in various ani-
mal models of epilepsy, especially those associated with inter-
ference in GABAergic transmission or provoked by excitatory
amino acids [18]. Gabapentin is an analogue of GABA that is
absorbed rapidly and it readily penetrates the blood-brain
barrier [19]. Despite extensive research, the mechanism of ac-
tion and the therapeutic range of serum concentration of ga-
bapentin remain unclear [20]. Gabapentin has been demon-
strated to activate glutamate decarboxylase [21] and
enhances the rate of synthesis of GABA in several regions
of the brain [22]. A recent study has demonstrated that gaba-
pentin binds to the K2N subunit of a calcium channel [23]. It
also reported that gabapentin activates GDH in rat brain
synaptosomes [24]. In vitro studies indicate an inhibition of
branched amino acid aminotransferase and interaction with
the L transport system [25]. Although numerous biochemical
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activities of gabapentin have been demonstrated, these have
not led to a clearer understanding of the anticonvulsant mech-
anism of this drug. At present it is unclear what its most
important site of action is and perhaps a novel receptor site
will be identi¢ed. It is also uncertain whether the primary site
of action is at the L system transporter itself, or whether there
is some interaction at the intracellular level.
In the present work, we have comparatively examined the
e¡ects of gabapentin on two di¡erent types of bovine brain
GDH isoproteins at various conditions in view of the central
role of GDH in cerebral metabolism. The studies provide
additional insight into the mechanism of action of gabapentin
on GDH activity.
2. Materials and methods
NADH, NADPH, NAD, NADP, 2-oxoglutarate, glutamate,
ADP, GTP, and L-leucine were purchased from Sigma Chemical
Co. Gabapentin was from Parke-Davis, Division of Warner-Lambert
Co. The GDH isoproteins were puri¢ed from bovine brain by the
method developed in our laboratory [11] and were homogeneous as
judged by Coomassie-stained gradient SDS-polyacrylamide gel elec-
trophoresis. All other chemicals and solvents were reagent grade or
better.
GDH activity was measured spectrophotometrically in the direction
of reductive amination of 2-oxoglutarate by following the decrease in
absorbance at 340 nm as described before [11]. All assays were per-
formed in duplicate, and initial velocity data were correlated with a
standard assay mixture containing 50 mM triethanolamine, pH 8.0,
100 mM ammonium acetate, 0.1 mM NADH, and 2.6 mM EDTA at
25‡C. GDH concentrations were adjusted to give a measured rate of
less than 0.04 absorbance units per min. The reaction started with the
addition of 2-oxoglutarate to a 10 mM ¢nal concentration. One unit
of enzyme was de¢ned as the amount of enzyme required to oxidize
1 Wmol of NADH per min at 25‡C. GDH activity was also measured
in the direction of glutamate oxidation in 50 mM Tris-HCl, pH 9.5
containing 1.4 mM NAD, and 2.6 mM EDTA at 25‡C. The reaction
was started by the addition of glutamate to a ¢nal concentration of
25 mM.
Unless otherwise speci¢ed, highly puri¢ed GDH fractions were used
for activation studies. Stimulation studies with gabapentin were per-
formed at various concentrations in assay bu¡er at 25‡C as described
in the ¢gure legends. Initial velocities were determined as described
above and the data were ¢tted by a least-squares method. For the
determination of the e¡ects of substrate concentration on the activa-
tion by gabapentin, the assays were carried out by varying the sub-
strate under investigation while keeping the other substrate and re-
agents at the optimal concentration indicated above. In some
experiments, the e¡ects of GTP on activation by gabapentin were
tested by including it in the incubation as described in the ¢gure
legends.
Unless otherwise mentioned, each experimental point represents the
mean of triplicate determinations from di¡erent preparations and the
standard deviation is indicated as an error bar in each ¢gure. At some
points, error bars were omitted in the ¢gures for clarity purposes.
3. Results and discussion
Gabapentin is a novel anticonvulsant drug, with a mecha-
nism of action apparently dissimilar to that of other antiepi-
leptic agents. In the present work, we have comparatively
examined the e¡ects of gabapentin on two di¡erent types of
bovine brain GDH isoproteins (GDH I and GDH II) in both
directions, oxidative deamination of glutamate and glutamate
formation, at various conditions. The results showed that reg-
ulation of enzyme activity by gabapentin was distinct for the
two GDH isoproteins. As shown in Fig. 1, the activities of
GDH isoproteins were enhanced 1.8^2.7-fold by addition of
gabapentin. When the e¡ects of di¡erent gabapentin concen-
trations on GDH activities were studied in the direction of
reductive amination of 2-oxoglutarate with NADPH as a
coenzyme, a marked activation was observed for both isopro-
teins, whereas both isoproteins showed activation to a lesser
extent with NADH as a coenzyme as shown in Fig. 1. There
were di¡erences between GDH I and GDH II in their sensi-
tivity to the action of gabapentin and half-maximal stimula-
tion was reached at 1.2^1.7 mM. The largest activation was
observed with GDH II when NADPH was used as a coen-
zyme (Fig. 1).
Stimulatory e¡ects of gabapentin on GDH activities in the
direction of the oxidative deamination of glutamate were also
observed, but to a much lesser extent than reductive amina-
tion as shown in Fig. 2. A slightly higher activation in a dose-
dependent manner was observed for GDH I when NADP
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Fig. 1. Activation of GDH isoproteins by gabapentin in the direc-
tion of reductive amination. GDH isoproteins were assayed in the
direction of reductive amination as described in Section 2 with 0.1
mM NADH or 0.1 mM NADPH. The relative activities are ex-
pressed as percentage of each control. b, GDH I with NADH; a,
GDH I with NADPH; F, GDH II with NADH; E, GDH II with
NADPH.
Fig. 2. Activation of GDH isoproteins by gabapentin in the direc-
tion of glutamate oxidation. GDH isoproteins were assayed in the
direction of glutamate oxidation as described in Section 2 with 1.4
mM NAD or 1.4 mM NADP. The relative activities are ex-
pressed as percentage of each control. b, GDH I with NAD ; a,
GDH I with NADP ; F, GDH II with NAD ; E, GDH II with
NADP.
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was used as a coenzyme (Fig. 2). The e¡ects, however, were
reversed in GDH II, showing a higher activation when as-
sayed with NAD (Fig. 2). The stimulatory e¡ects of gaba-
pentin on GDH isoproteins are complex depending on sub-
strate and coenzyme used (Figs. 1 and 2). We do not have a
clear explanation for this complexity at this time. Similar re-
sults, however, have been obtained by others [26] who re-
ported complex e¡ects of ATP and ADP on GDH depending
on pH, substrate and coenzyme used. Very recently, another
study [16] showed that two human GDH isoproteins di¡er in
their relative sensitivity to ADP.
The e¡ective concentration of gabapentin used in our study
to give half-maximal stimulation is about 1.5 mM. The ther-
apeutic range of serum concentrations of gabapentin has not
been established yet [20]. According to recent reports, daily
doses of 1200^1400 mg (7^8 mmol) (standard dose) and 3300^
3600 mg (19^21 mmol) (high dose) have been frequently used
[20,27]. Since gabapentin has a volume of distribution of ap-
proximately 58 liters [20], the daily high dose of the drug
corresponds to approximately 0.4 mM. Therefore, the e¡ec-
tive concentration of gabapentin used in our study is slightly
higher than the clinically used concentrations of the drug.
Besides, our results are quite consistent with a half-maximal
stimulation of GDH in rat brain synaptosomes (1.5 mM)
previously reported by Goldlust et al. [24].
GTP is known to be an inhibitor of GDH [28,29] and our
previous work also showed that the bovine brain GDH iso-
proteins were inhibited by GTP to di¡erent extents [12]. The
concentrations of GTP necessary to give 50% inhibition were
between 0.5 and 3.0 WM depending on the GDH isoproteins
and the assay conditions [12]. GDH from Neurospora crassa,
however, is not regulated by GTP. This enzyme contains 48
fewer residues than mammalian GDH, and there is little iden-
tity between the 100 residues in the C-terminus [30]. Studies
have shown that chemical probes can at least partially desen-
sitize bovine liver GDH to GTP inhibition while not a¡ecting
catalytic activity. The amino acids modi¢ed by these chemical
probes were shown to be a residue in the C-terminus [31]. It
seems likely that the regulatory GTP binding domain is lo-
cated in the C-terminal half of GDH [12,29]. The e¡ects of
GTP on activation by gabapentin was studied for both GDH
I and GDH II. As shown in Fig. 3A, gabapentin relieved the
inhibition of GDH I by GTP and this resulted in an increase
in the apparent activation by gabapentin in the presence of
GTP. Similar e¡ects, but to di¡erent extents, were observed
with GDH II as shown in Fig. 3B. Therefore, qualitatively,
GTP showed similar e¡ects on the activation of both GDH I
and GDH II by gabapentin, however, there were quantitative
di¡erences, as shown in Fig. 3. Since inhibition of GDH by
GTP and the high substrate inhibition by NADH have been
shown to potentiate each other [32], the observed e¡ects of
gabapentin on GTP inhibition might be consistent with its
e¡ects on NADH inhibition. The in vivo roles of gabapentin
on the inhibition of GDH isoproteins by GTP, however, still
remain to be resolved, since the magnesium complexes of
GTP, which may be the predominant forms, have little inhib-
itory e¡ect on GDH [28].
Fig. 4A shows the e¡ects of substrate concentration on the
activation of GDH I by gabapentin. The results of varying the
concentration of 2-oxoglutarate at two di¡erent ¢xed concen-
trations of NADH (0.1 mM and 0.2 mM) in the presence and
absence of 4 mM gabapentin are shown. The higher concen-
tration of 0.2 mM NADH was in the range giving inhibition
by this coenzyme. 2-Oxoglutarate was found to give rise to
high substrate inhibition both in the absence and in the pres-
ence of 4 mM gabapentin. Gabapentin, however, reduced the
substrate inhibition in the presence of 0.2 mM NADH. The
e¡ects of substrate concentration on the activation of GDH II
by gabapentin were similar to those obtained with GDH I, as
shown in Fig. 4B. The apparently linear portions of the dou-
ble-reciprocal plots with varied glutamate concentrations
showed similar slopes in the presence and absence of gaba-
pentin as appeared to be true when 2-oxoglutarate was varied
(data not shown). Thus, the e¡ects of gabapentin may com-
prise a direct e¡ect on the enzyme together with a relief of
high substrate inhibition.
It has been well documented that ADP and leucine are
activators of GDH and they have also been known to reduce
high substrate inhibition by NADH [11,26]. Activation of
GDH isoproteins by gabapentin is similar to the regulation
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Fig. 3. E¡ect of GTP on the activation of GDH isoproteins by gabapentin. The enzymes were assayed in the direction of reductive amination
as described in Section 2 with 0.1 mM NADH at various concentrations of GTP. The relative activities are expressed as percentage of each
control. The GTP concentrations were 0.0 WM (F), 1.0 WM (a), and 2.0 WM (b). A: GDH I. B: GDH II.
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by leucine. It was reported that the GDH from rat synapto-
somes is activated by leucine and by its non-metabolizable
analogue 2-amino-bicyclo(2,2,1)heptane-2-carboxylic acid
[33]. The half-maximal concentration of leucine for decreasing
glutamate formation was approximately 1 mM. Although the
concentration of leucine in brain ranges from 0.1 to 0.2 mM,
it has been suggested that leucine may activate GDH in
pathological conditions where leucine concentrations are ele-
vated [34]. In the present work, the activities of the GDH
isoproteins obtained at saturating concentrations (10 mM)
of gabapentin were not increased further by subsequent addi-
tion of either 0.1 mM ADP or 1 mM leucine (data not
shown). Activation of GDH provides an example where ga-
bapentin biochemically mimics the action of leucine, although
the potential physiological role of gabapentin remains to be
resolved. Gabapentin was previously reported to compete
with leucine at system L transporters [25] as well as at high
a⁄nity binding sites in the brain [35]. If leucine plays a sig-
ni¢cant role in a neurotransmitter function, the functional
similarity between leucine and gabapentin may account for
at least part of the pharmacological actions of gabapentin.
As suggested by Goldlust et al. [24], studies of the similarities
and di¡erences between gabapentin and leucine in various
CNS functions may provide more insight into the mechanism
of action of gabapentin.
As many proteins have functions distinct from those for
which they were originally identi¢ed, it will also be of interest
to assess the other roles of GDH isoproteins. Recently, Preiss
et al. [36] showed that GDH, previously reported to be able to
bind RNA, is the cytochrome c oxidase transcript binding
protein. It has also been reported that a membrane-bound
form of GDH is involved in the association of lysosomes to
microtubules [37]. Very recently, a novel nerve tissue-speci¢c
human GDH, with a thermostability and ADP regulation
dissimilar to those of previously reported human GDH, was
identi¢ed [16]. It remains to be studied whether the distinct
properties of the brain GDH isoproteins are essential for the
regulation of glutamate metabolism.
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